載入中
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
前收盤價
US$16.01
−US$0.48 · -2.91%
盤後
US$16.50
+US$0.49 · +3.06%
10月15日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
日內區間
目前US$16.01
52週區間
目前US$16.01
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
57
合理估值
情緒
57
多空交錯
風險
47
風險偏高
動能
85
強勢上行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
日內區間
目前US$16.01
52週區間
目前US$16.01
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 營收 | 649.7萬 USD | 148.7萬 USD | — | — |
| 毛利 | 649.7萬 USD | 148.7萬 USD | — | — |
| 研究與開發 | 6745.1萬 USD | 4095.4萬 USD | 2591.9萬 USD | 1430.2萬 USD |
| 銷售、一般及管理費用 | 1259.8萬 USD | 1130.7萬 USD | 767.9萬 USD | 510.6萬 USD |
| 營業費用 | 8118.1萬 USD | 5353.7萬 USD | 3479.4萬 USD | 1976.4萬 USD |
| 利息收入 | 1100.9萬 USD | 810.3萬 USD | 537.7萬 USD | 164.7萬 USD |
| 折舊和攤銷 | 232.9萬 USD | 157.5萬 USD | 112萬 USD | 44.5萬 USD |
| 營業利益 | −7468.4萬 USD | −5205萬 USD | −3479.4萬 USD | −1976.4萬 USD |
| 淨利 | −6373.1萬 USD | −4398萬 USD | −2864.1萬 USD | −1792.9萬 USD |
公司資料更新於 2026年10月16日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1662.12萬0.00%2.3兆 USD0.03%US$378.42+0.41%
iShares Russell 2000 ETFIWM1245.66萬0.02%755.95億 USD0.19%US$275.08+1.37%
State Street SPDR S&P Biotech ETFXBI882.9萬0.09%100.69億 USD0.35%US$149.78+2.05%
Vanguard Extended Market ETFVXF570.51萬0.01%912億 USD0.05%US$230.72+1.30%
Vanguard Russell 2000 ETFVTWO323.35萬0.02%173億 USD0.06%US$111.09+1.35%
iShares Russell 2000 Growth ETFIWO299.01萬0.02%133.86億 USD0.24%US$347.65+1.41%
Schwab U.S. Small-Cap ETFSCHA221.84萬0.01%216.55億 USD0.03%US$32.49+1.56%
Truth Social God Bless America ETFYALL106.02萬1.31%8107.42萬 USD0.65%US$42.92+0.37%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHATruth Social God Bless America ETFYALLAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
